Ronald R De Krijger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/895399/publications.pdf

Version: 2024-02-01

61 papers

3,603 citations

201674 27 h-index 56 g-index

62 all docs 62 docs citations

62 times ranked 4746 citing authors

#	Article	IF	CITATIONS
1	Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only â^ the SIOP 93–01 and 2001 protocols. European Journal of Cancer, 2022, 163, 88-97.	2.8	8
2	Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy. Cancers, 2022, 14, 943.	3.7	4
3	Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocrine Pathology, 2022, 33, 155-196.	9.0	87
4	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 50-61.	2.0	18
5	The diagnostic value of magnetic resonance imaging in differentiating benign and malignant pediatric ovarian tumors. Pediatric Radiology, 2021, 51, 427-434.	2.0	9
6	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. Science Advances, 2021, 7, .	10.3	78
7	Clinical and Molecular Characteristics and Outcome of Cystic Partially Differentiated Nephroblastoma and Cystic Nephroma: A Narrative Review of the Literature. Cancers, 2021, 13, 997.	3.7	11
8	Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers, 2021, 13, 3142.	3.7	27
9	Locoregional control using highly conformal flank target volumes and volumetric-modulated arc therapy in pediatric renal tumors: Results from the Dutch national cohort. Radiotherapy and Oncology, 2021, 159, 249-254.	0.6	10
10	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2021, 185, 179-191.	3.7	12
11	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Reports, 2021, 36, 109568.	6.4	25
12	Interobserver variability between experienced and inexperienced observers in the histopathological analysis of Wilms tumors: a pilot study for future algorithmic approach. Diagnostic Pathology, 2021, 16, 77.	2.0	4
13	Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis. Cancers, 2021, 13, 4941.	3.7	1
14	Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the Literature. Journal of Clinical Medicine, 2021, 10, 5558.	2.4	6
15	MR imaging in discriminating between benign and malignant paediatric ovarian masses: a systematic review. European Radiology, 2020, 30, 1166-1181.	4.5	23
16	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers, 2020, 12, 1776.	3.7	29
17	Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Scientific Reports, 2020, 10, 17667.	3.3	20
18	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. Journal of Pathology, 2020, 251, 378-387.	4.5	23

#	Article	IF	Citations
19	Renal Tumors of Childhoodâ€"A Histopathologic Pattern-Based Diagnostic Approach. Cancers, 2020, 12, 729.	3.7	25
20	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 2020, 11, 1310.	12.8	183
21	Title is missing!. , 2020, 15, e0242167.		0
22	Title is missing!. , 2020, 15, e0242167.		0
23	Title is missing!. , 2020, 15, e0242167.		0
24	Title is missing!. , 2020, 15, e0242167.		0
25	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	7.1	57
26	Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin. Cancers, 2019, 11, 1070.	3.7	35
27	Molecular Alterations in Dog Pheochromocytomas and Paragangliomas. Cancers, 2019, 11, 607.	3.7	13
28	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. Endocrine, 2019, 64, 673-684.	2.3	23
29	Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. European Journal of Internal Medicine, 2018, 51, 68-73.	2.2	160
30	Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 46-55.	3.6	19
31	Pathology and genetics of phaeochromocytoma and paraganglioma. Histopathology, 2018, 72, 97-105.	2.9	120
32	European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 2018, 179, G1-G46.	3.7	559
33	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
34	False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (18F-FDOPA-PET) performed for imaging of neuroendocrine tumors. European Journal of Endocrinology, 2018, 179, 125-133.	3.7	19
35	Impact of early- and late-onset preeclampsia on features of placental and newborn vascular health. Placenta, 2017, 49, 72-79.	1.5	48
36	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	3.6	33

#	Article	IF	CITATIONS
37	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
38	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	3.7	75
39	Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. Human Pathology, 2016, 58, 113-122.	2.0	25
40	Porphyromonas gingivalis within Placental Villous Mesenchyme and Umbilical Cord Stroma Is Associated with Adverse Pregnancy Outcome. PLoS ONE, 2016, 11, e0146157.	2.5	61
41	Tissue-Specific Suppression of Thyroid Hormone Signaling in Various Mouse Models of Aging. PLoS ONE, 2016, 11, e0149941.	2.5	23
42	Somatic RET mutation in a patient with pigmented adrenal pheochromocytoma. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 150117.	0.5	2
43	The clinical utility of reticular basement membrane thickness measurements in asthmatic children. Journal of Asthma, 2015, 52, 926-930.	1.7	9
44	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5.5	176
45	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	3.6	274
46	Altered Phenotype of \hat{l}^2 -Cells and Other Pancreatic Cell Lineages in Patients With Diffuse Congenital Hyperinsulinism in Infancy Caused by Mutations in the ATP-Sensitive K-Channel. Diabetes, 2015, 64, 3182-3188.	0.6	20
47	Toward an improved definition of the genetic and tumor spectrum associated with SDH germ-line mutations. Genetics in Medicine, 2015, 17, 610-620.	2.4	91
48	Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects. European Journal of Human Genetics, 2015, 23, 922-928.	2.8	70
49	Vascular Pattern Analysis for the Prediction of Clinical Behaviour in Pheochromocytomas and Paragangliomas. PLoS ONE, 2015, 10, e0121361.	2.5	14
50	TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney. Oncotarget, 2015, 6, 15828-15841.	1.8	46
51	Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma. Oncotarget, 2015, 6, 39111-39126.	1.8	15
52	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. Endocrine-Related Cancer, 2014, 21, 601-613.	3.1	25
53	Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome. Neoplasia, 2014, 16, 868-873.	5. 3	55
54	The window period of NEUROGENIN3 during human gestation. Islets, 2014, 6, e954436.	1.8	47

#	Article	IF	CITATIONS
55	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
56	Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. Endocrine-Related Cancer, 2014, 21, 653-661.	3.1	39
57	Automated Selection of Hotspots (ASH): enhanced automated segmentation and adaptive step finding for Ki67 hotspot detection in adrenal cortical cancer. Diagnostic Pathology, 2014, 9, 216.	2.0	33
58	Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation. PLoS ONE, 2014, 9, e104944.	2.5	10
59	High Anaplastic Lymphoma Kinase Immunohistochemical Staining in Neuroblastoma and Ganglioneuroblastoma Is an Independent Predictor of Poor Outcome. American Journal of Pathology, 2012, 180, 1223-1231.	3.8	60
60	Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 9-18.	2.8	59
61	Molecular genetic analysis of the von Hippel-Lindau and human peroxisome proliferator-activated receptor? tumor-suppressor genes in adenocarcinomas of the gastroesophageal junction. International Journal of Cancer, 2001, 94, 891-895.	5.1	17